Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI3K Pathway Analysis in Everolimus + Exemestane for Breast Cancer
NCT02109913Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2014
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in breast cancer, sponsored by Amsterdam University Medical Center. Primary endpoints: Biomarker Evaluation from Primary Tumor Tissue, New Tumor Biopsies and Blood Samples and Progression-free survival. Status: unknown.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02109913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109913.